Inhibikase Therapeutics presents Phase 1/1b data for IkT-148009 in Parkinson's; Phase 2 ongoing

Inhibikase Therapeutics, Inc.

Phase 1/1b of IkT-148009 (88 healthy, 13 PD patients) showed no clinically significant AEs, linear PK, and CNS penetration over 12.5-325 mg daily doses.
In PD mouse models, once-daily oral IkT-148009 preserved >80% SNpc neurons, improved motor function, and reduced pathological alpha-synuclein aggregates.
C-Abl activation is required for PD initiation; IkT-148009 is a selective brain-penetrant c-Abl inhibitor with no organ toxicity seen in toxicology studies.
Phase 2 3-month dosing study (NCT05424276) in mild-to-moderate PD patients has begun to evaluate efficacy and disease modification.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.